Zeo Scientifix, Inc.

Market Cap $20.01M
Debt $725.00K
Cash $1.11M
EV $19.63M
FCF $NaN

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$4.54M
EBIT	-$5.13M
ROA	-231%
Equity	-$1.42M
Growth Stability	1
PE	-4.41
PB	-14.08
P/S	4.17
Price/Cash	0.06
Debt/Equity	-0.51
Net Margins	-102%
Gross Margins	84%
Op. Margins	-107%
Sales Growth YoY	-11%
Sales Growth QoQ	-4%
Sales CAGR	58%
Earnings Growth YoY	-37%
Earnings Growth QoQ	-28%

Sales CAGR 5Y	20%
Earnings CAGR 3Y	-11%
Sales CAGR 3Y	-11%
Market Cap	$20.01M
Revenue	$4.80M
Assets	$2.22M
Total Debt	$725.00K
Cash	$1.11M
Shares Outstanding	6.25M
EV	19.63M
Working Capital	-1.91M
Current Ratio	0.47
Gross Profit	$4.05M
Shares Growth 3y	-18%
Equity Growth QoQ	-16%
Equity Growth YoY	39%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Organicell Regenerative Medicine Inc is engaged in the healthcare industry, principally focusing on supplying products and services related to the growing field of regenerative anti-aging medicine (RAAM). It mainly focuses on supplying biologically processed cellular and tissue-based products and providing other related services used in the growing healthcare field of regenerative medicine. The company distributes RAAM products and market RAAM-related services to the healthcare industry and a referral network of doctors and clinics.

SEC Filings

Direct access to Zeo Scientifix, Inc. (ZEOX) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Jul 31
- 10-Q Apr 30
- 10-Q Jan 31
2023
- 10-K Oct 31
- 10-Q Jul 31
- 10-Q Apr 30
- 10-Q Jan 31
2022
- 10-K Oct 31
- 10-Q Jul 31
- 10-Q Apr 30
- 10-Q Jan 31

Sector Comparison

How does Zeo Scientifix, Inc. compare to its competitors?

Not enough data to generate a comparison chart between Zeo Scientifix, Inc. and its competitors. Please check back later.

Peter Lynch's Chart

This chart shows the current pricing of Zeo Scientifix, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Zeo Scientifix, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Zeo Scientifix, Inc..

Years

Calculation mode

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
DCF		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Value	$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	10/2015	10/2016	10/2017	10/2018	10/2019	10/2020	10/2021	10/2022	10/2023	TTM
Net Margins	-500%	-678%	-2K%	-359%	-102%	-412%	-228%	-137%	-153%	-102%
ROA	-	-1K%	-2K%	-3K%	-278%	-932%	-659%	-143%	-243%	-231%
ROE	-	160%	260%	285%	111%	904%	479%	-471%	563%	-

Bad Net Margins (-102.22%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	10/2015	10/2016	10/2017	10/2018	10/2019	10/2020	10/2021	10/2022	10/2023	TTM
Debt over FCF	-	-0.17	-0.11	-0.62	-0.62	-0.09	-0.05	-0.14	-0.33	-
Debt over Equity	-	-0.13	-0.03	-0.26	-0.24	-0.13	-0.05	0.3	-0.58	-0.51
Growth Stability	-	-	-	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Good Debt/Equity ratio (-0.51)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	10/2015	10/2016	10/2017	10/2018	10/2019	10/2020	10/2021	10/2022	10/2023	CAGR 5Y
Revenue YoY growth	-	25%	208%	69%	76%	80%	83%	16%	-30%	20%
Earnings YoY growth	-	70%	627%	-62%	-50%	624%	1%	-30%	-21%	-
Equity YoY growth	-	-6K%	347%	-65%	29%	-11%	92%	-171%	-166%	-
FCF YoY growth	-	46%	61%	-44%	16%	226%	59%	29%	-44%	-